Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. NOVO
  4. NOVO — Marts 2026

NOVO — Marts 2026

Planlagt Fastgjort Låst Flyttet NOVO
409 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    EIMiller
    wrote on sidst redigeret af
    #125

    Jeg havde håbet at Novo har bedre lidt snor i HIMS, fx. gennem max. antal compounds og end-date for konvertering af eksisterende patienter til novo produkter.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      pauly
      wrote on sidst redigeret af
      #126

      Compounding i et begrænset omfang kan vi leve med og det ville også være i tråd med lovgivningen. Vi må håbe det er sådan det bliver

      1 Reply Last reply
      0
      • nohopeN Offline
        nohopeN Offline
        nohope
        wrote on sidst redigeret af
        #127

        Synes den aftale er altfor god for Hims.

        1 Reply Last reply
        0
        • AlbertoA Offline
          AlbertoA Offline
          Alberto
          wrote on sidst redigeret af
          #128

          ElMiller 21:45 - Novo har stadig søgsmålet og kan aktivere det, hvis de finder det nødigt! - Hvad Mike D. ikke mente, det blev... Jeg er ellers enig: Det ser ikke ud til at være forhandlet godt nok: Men HIMS er vigtig for distributionen og dermed volumen! Og volumen er alt, det drejer sig om nu!

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #129

            Novo Nordisk betaler yderligere 50 mio. dollar til udviklingspartner https://proinvestor.com/investornyt/1419581/novo-nordisk-betaler-yderligere-50-mio-dollar-til-udviklingspartner

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #130

              Novo: Amerikansk børshus skruer anbefalingen ned til neutralt niveau
              https://proinvestor.com/investornyt/1419580/novo-amerikansk-borshus-skruer-anbefalingen-ned-til-neutralt-niveau

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #131

                Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market share

                Link Preview Image
                Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market share

                Novo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide in the anti-obesity market. Price reductions and increased availability are driving this surge. Semaglutide's market share has significantly increased, narrowing the gap with its competitor. This trend is expected to continue as Novo Nordisk expands its reach.

                favicon

                The Economic Times (economictimes.indiatimes.com)

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #132

                  Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock https://www.fool.com/investing/2026/03/09/novo-nordisk-is-slashing-prices-for-ozempic-and-we/

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    ProinvestorNEWS
                    wrote on sidst redigeret af
                    #133

                    Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-says-some-medicare-plans-may-exceed-50-cap-weight-loss-drugs-2026-03-09/

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #134

                      Novos aftale med Hims & Hers giver begrænset rygstød mener amerikanske storbank https://proinvestor.com/investornyt/1419590/novos-aftale-med-hims-hers-giver-begraenset-rygstod-mener-amerikanske-storbank

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #135

                        Video: Denne episode af The Downsized News gennemgår flere vigtige udviklinger i den hastigt udviklende verden af ​​GLP-1-medicin og fedmebehandling. Christopher og Laraine Durham gennemgår den seneste forskning, regulatoriske tiltag og brancheændringer, der påvirker folk, der bruger medicin som Zepbound, Mounjaro, Wegovy og Ozempic til at behandle fedmesygdommen. https://proinvestor.com/boards/131485

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          EIMiller
                          wrote on sidst redigeret af
                          #136

                          Alberto 6:54 - jeg håber ikke vi kommer til at sige: fool me once shame on you,
                          fool me twice shame on me

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #137

                            As federal regulators intensify scrutiny of compounded GLP-1 drugs and telehealth marketing practices, two developments in early March 2026 signal a turning point for the industry: a wave of FDA enforcement actions and a high-profile resolution between Hims & Hers Health and Novo Nordisk. https://www.frierlevitt.com/articles/fda-warning-letters-hims-novo-nordisk-compounded-glp1/

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              pauly
                              wrote on sidst redigeret af
                              #138

                              Tak PN spændende skriv

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #139

                                Novo Nordisk bekræfter advarselsbrev fra FDA https://proinvestor.com/investornyt/1419761/novo-nordisk-bekraefter-advarselsbrev-fra-fda

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  mauri
                                  wrote on sidst redigeret af
                                  #140

                                  Grande azienda! Grande CEO! ....e anche oggi un bel -3% non ce lo toglie nessuno!

                                  1 Reply Last reply
                                  0
                                  • CupcakeC Offline
                                    CupcakeC Offline
                                    Cupcake
                                    wrote on sidst redigeret af
                                    #141

                                    Ad PN 16:47 - Så FDA kritiserer Novos bivirknings-systemer i denne tid, hvor semaglutid eksploderer globalt. Har Novo ikke styr på det? PS Novo fik observationerne i feb 2025 og har haft omkring et år (!) til at adressere dem, før FDA valgte at sende et egentligt advarselsbrev. Er det normalt? Og besynderligt, at modsat Novo, så kunne FDA identificere afdøde….

                                    1 Reply Last reply
                                    0
                                    • CupcakeC Offline
                                      CupcakeC Offline
                                      Cupcake
                                      wrote on sidst redigeret af
                                      #142

                                      Novo USA Statement vedr FDA https://www.novonordisk-us.com/media/news-archive/news-details.html

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #143

                                        Grupo Santander has initiated coverage of $NVO with an Outperform rating.

                                        The bank also sets a price target of DKK 366.84.

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #144

                                          Olieprisen eksploderer efter USA's angreb i Iran, og frygten rammer aktiemarkedet. Hansen og Larsen analyserer, hvorfor Zealand Pharma og Gubra falder på gode data, og om Novo Nordisk har lavet en fejl med HIMS-aftalen. Hør om alt dette og meget mere i denne uges afsnit af Investeringspodcasten. https://proinvestor.com/boards/131498

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper